Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals.

Wang C, Hockerman S, Jacobsen EJ, Alippe Y, Selness SR, Hope HR, Hirsch JL, Mnich SJ, Saabye MJ, Hood WF, Bonar SL, Abu-Amer Y, Haimovich A, Hoffman HM, Monahan JB, Mbalaviele G.

J Exp Med. 2018 May 7;215(5):1315-1325. doi: 10.1084/jem.20172063. Epub 2018 Mar 16.

2.

Techniques used to characterize the binding of cyclooxygenase inhibitors to the cyclooxygenase active site.

Hood WF.

Methods Mol Biol. 2010;644:121-9. doi: 10.1007/978-1-59745-364-6_10.

PMID:
20645169
3.

A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.

Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, Schindler JF, South SA, Webb EG, Zhang J, Anderson DR.

J Pharmacol Exp Ther. 2010 Jun;333(3):797-807. doi: 10.1124/jpet.110.166173. Epub 2010 Mar 17.

PMID:
20237073
4.

Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides.

Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, Woodard SS, Chrencik J, Hood WF, Schindler JF, Kishore N, Mbalaviele G.

J Biol Chem. 2010 Apr 30;285(18):13498-506. doi: 10.1074/jbc.M109.099895. Epub 2010 Feb 18.

5.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
6.

Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB.

Mol Pharmacol. 2003 Apr;63(4):870-7.

PMID:
12644588
7.

Examination of the kinetic mechanism of mitogen-activated protein kinase activated protein kinase-2.

Schindler JF, Godbey A, Hood WF, Bolten SL, Broadus RM, Kasten TP, Cassely AJ, Hirsch JL, Merwood MA, Nagy MA, Fok KF, Saabye MJ, Morgan HM, Compton RP, Mourey RJ, Wittwer AJ, Monahan JB.

Biochim Biophys Acta. 2002 Jul 29;1598(1-2):88-97.

PMID:
12147348
8.

Modulation of the binding affinity of myelopoietins for the interleukin-3 receptor by the granulocyte colony-stimulating factor receptor agonist.

Hood WF, Feng YG, Schilling RJ, Gokarn Y, Jarvis C, Remsen EE, Shieh JJ, Joy W, Klein BK, Polazzi JO, Welply JK, McKearn JP, Monahan JB.

Biochemistry. 2001 Nov 13;40(45):13598-606.

PMID:
11695908
9.
10.

Progenipoietins: biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor.

Streeter PR, Minster NI, Kahn LE, Hood WF, Vickery LE, Thurman TL, Monahan JB, Welply JK, McKearn JP, Woulfe SL.

Exp Hematol. 2001 Jan;29(1):41-50.

PMID:
11164104
11.

Structural insights into the stereochemistry of the cyclooxygenase reaction.

Kiefer JR, Pawlitz JL, Moreland KT, Stegeman RA, Hood WF, Gierse JK, Stevens AM, Goodwin DC, Rowlinson SW, Marnett LJ, Stallings WC, Kurumbail RG.

Nature. 2000 May 4;405(6782):97-101.

PMID:
10811226
12.

Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties.

Klein BK, Olins PO, Bauer SC, Caparon MH, Easton AM, Braford SR, Abrams MA, Klover JA, Paik K, Thomas JW, Hood WF, Shieh JJ, Polazzi JO, Donnelly AM, Zeng DL, Welply JK, McKearn JP.

Exp Hematol. 1999 Dec;27(12):1746-56.

PMID:
10641592
13.

Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin.

McWherter CA, Feng Y, Zurfluh LL, Klein BK, Baganoff MP, Polazzi JO, Hood WF, Paik K, Abegg AL, Grabbe ES, Shieh JJ, Donnelly AM, McKearn JP.

Biochemistry. 1999 Apr 6;38(14):4564-71.

PMID:
10194378
14.

Circular permutation of granulocyte colony-stimulating factor.

Feng Y, Minnerly JC, Zurfluh LL, Joy WD, Hood WF, Abegg AL, Grabbe ES, Shieh JJ, Thurman TL, McKearn JP, McWherter CA.

Biochemistry. 1999 Apr 6;38(14):4553-63.

PMID:
10194377
15.

The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling.

Klein BK, Feng Y, McWherter CA, Hood WF, Paik K, McKearn JP.

J Biol Chem. 1997 Sep 5;272(36):22630-41.

16.

Multiple conformations of a human interleukin-3 variant.

Feng Y, Hood WF, Forgey RW, Abegg AL, Caparon MH, Thiele BR, Leimgruber RM, McWherter CA.

Protein Sci. 1997 Aug;6(8):1777-82.

17.

Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3.

Thomas JW, Baum CM, Hood WF, Klein B, Monahan JB, Paik K, Staten N, Abrams M, McKearn JP.

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3779-83.

18.

Characterization of indole-2-carboxylate derivatives as antagonists of N-methyl-D-aspartate receptor activity at the associated glycine recognition site.

Hood WF, Gray NM, Dappen MS, Watson GB, Compton RP, Cordi AA, Lanthorn TH, Monahan JB.

J Pharmacol Exp Ther. 1992 Aug;262(2):654-60.

PMID:
1386886
19.

Characterization of 3-carboxy-5-phosphono-1,2,3,4-tetrahydroisoquinoline (SC-48981), a potent competitive N-methy-D-aspartate (NMDA) receptor antagonist, in vitro and in vivo.

Vazquez ML, Garland DJ, Sun ET, Cler JA, Mick SJ, Hood WF, Monahan JB, Iyengar S, Rao TS.

Neurosci Lett. 1992 Feb 3;135(2):149-52.

PMID:
1352628
20.

Synthesis, absolute configuration and activity at N-methyl-D-aspartic acid (NMDA) receptor of the four D-2-amino-4,5-methano-adipate diastereoisomers.

Pellicciari R, Natalini B, Marinozzi M, Sadeghpour BM, Cordi AA, Lanthorn TH, Hood WF, Monahan JB.

Farmaco. 1991 Nov;46(11):1243-64.

PMID:
1667358
21.

Novel indole-2-carboxylates as ligands for the strychnine-insensitive N-methyl-D-aspartate-linked glycine receptor.

Gray NM, Dappen MS, Cheng BK, Cordi AA, Biesterfeldt JP, Hood WF, Monahan JB.

J Med Chem. 1991 Apr;34(4):1283-92.

PMID:
1849994
22.
23.

Cis-2,4-methanoglutamate is a potent and selective N-methyl-D-aspartate receptor agonist.

Lanthorn TH, Hood WF, Watson GB, Compton RP, Rader RK, Gaoni Y, Monahan JB.

Eur J Pharmacol. 1990 Jul 17;182(3):397-404.

PMID:
2146136
24.

Differential modulation of the associated glycine recognition site by competitive N-methyl-D-aspartate receptor antagonists.

Monahan JB, Biesterfeldt JP, Hood WF, Compton RP, Cordi AA, Vazquez MI, Lanthorn TH, Wood PL.

Mol Pharmacol. 1990 Jun;37(6):780-4.

PMID:
2163012
25.

Characterization of D-3,4-cyclopropylglutamates as N-methyl-D-aspartate receptor agonists.

Monahan JB, Hood WF, Compton RP, Cordi AA, Snyder JP, Pellicciari R, Natalini B.

Neurosci Lett. 1990 May 4;112(2-3):328-32.

PMID:
2163042
26.

N-methyl-D-aspartate recognition site ligands modulate activity at the coupled glycine recognition site.

Hood WF, Compton RP, Monahan JB.

J Neurochem. 1990 Mar;54(3):1040-6.

PMID:
1968086
27.

Evidence for a functional coupling of the NMDA and glycine recognition sites in synaptic plasma membranes.

Compton RP, Hood WF, Monahan JB.

Eur J Pharmacol. 1990 Jan 23;188(1):63-70.

PMID:
2155123
28.

Guanine nucleotide modulation of [3H]TCP binding to the NMDA receptor complex.

Hood WF, Thomas JW, Compton RP, Monahan JB.

Eur J Pharmacol. 1990 Jan 23;188(1):43-9.

PMID:
2155121
29.

D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats.

Monahan JB, Handelmann GE, Hood WF, Cordi AA.

Pharmacol Biochem Behav. 1989 Nov;34(3):649-53.

PMID:
2560209
30.

Characterization of a [3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex.

Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP.

J Neurochem. 1989 Aug;53(2):370-5.

PMID:
2545816
31.
32.

1-Aminocyclobutane-1-carboxylate (ACBC): a specific antagonist of the N-methyl-D-aspartate receptor coupled glycine receptor.

Hood WF, Sun ET, Compton RP, Monahan JB.

Eur J Pharmacol. 1989 Feb 28;161(2-3):281-2. No abstract available.

PMID:
2542048
33.

Effects of guanine nucleotides on N-methyl-D-aspartate receptor-ligand interactions.

Monahan JB, Hood WF, Michel J, Compton RP.

Mol Pharmacol. 1988 Aug;34(2):111-6.

PMID:
2842650
34.

Glycine modulation of the phencyclidine binding site in mammalian brain.

Thomas JW, Hood WF, Monahan JB, Contreras PC, O'Donohue TL.

Brain Res. 1988 Mar 1;442(2):396-8.

PMID:
2836022
35.

Determination of the pharmacokinetics of 2-amino-7-phosphonoheptanoate in rat plasma and cerebrospinal fluid.

Compton RP, Hood WF, Monahan JB.

Neurosci Lett. 1988 Feb 3;84(3):339-44.

PMID:
3352960
36.

Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids.

Pullan LM, Olney JW, Price MT, Compton RP, Hood WF, Michel J, Monahan JB.

J Neurochem. 1987 Oct;49(4):1301-7.

PMID:
2887637
37.
38.
39.
40.
42.
43.

Inhibition of synaptosomal calcium uptake by ethanol.

Harris RA, Hood WF.

J Pharmacol Exp Ther. 1980 Jun;213(3):562-8.

PMID:
7193727
44.

Effects of depressant drugs and sulfhydryl reagents on the transport of calcium by isolated nerve endings.

Hood WF, Harris RA.

Biochem Pharmacol. 1980 Mar 15;29(6):957-9. No abstract available.

PMID:
7387713
45.

Effects of pentobarbital, ethanol and morphine on subcellular localization of calcium and magnesium in brain.

Hood WF, Harris RA.

Biochem Pharmacol. 1979 Oct 15;28(20):3075-80. No abstract available.

PMID:
518706

Supplemental Content

Support Center